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Abstract To assess peroxynitrite formation in lipopolysaccha-
ride (LPS)-stimulated human blood, we have measured nitric
oxide (NO)-dependent intracellular oxidation of dihydrorhod-
amine 123 (DHR 123) to rhodamine. LPS increased DHR 123
oxidation in neutrophil granulocytes, monocytes and lympho-
cytes in a time-dependent fashion. Greater extent of DHR 123
oxidation was detected in neutrophils and monocytes than in
lymphocytes. These changes were accompanied by accumulation
of rhodamine in the plasma. While intracellular DHR 123
oxidation and rhodamine accumulation in the plasma were not
affected by inhibition of constitutive NO synthase at 30 and 60
min after addition of LPS, they were markedly attenuated by
inhibition of inducible NO synthase at 4, 8, 16 and 24 h after
addition of LPS. These results demonstrate that human
leukocytes can produce high amounts of peroxynitrite in response
to LPS, and may contribute to the elevated plasma peroxynitrite
levels observed during endotoxic shock.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
An increasing body of evidence indicates that several ac-
tions of nitric oxide (NO) are mediated in part by peroxyni-
trite (ONOO3), a potent oxidant formed by the reaction of
NO with superoxide at an almost di¡usion-controlled rate
[1,2]. In many pathologic conditions, simultaneous cellular
production of superoxide and NO may occur, potentially
leading to the formation of ONOO3. Indeed, ONOO3 for-
mation has been demonstrated in activated macrophages [3]
and endothelial cells [4], in acute respiratory distress syn-
drome [5], in£ammatory bowel disease [6,7], ischemia reperfu-
sion [1,6], rheumatoid arthritis [8] and septic shock [9,10].
Both the early and delayed phases of endotoxic shock are
associated with enhanced ONOO3 formation. Peroxynitrite-
mediated oxidation of dihydrorhodamine 123 (DHR 123) was
detected in the rat plasma in the early stages of endotoxic
shock [10]. A substantial increase in nitrotyrosine immuno-
reactivity has been demonstrated in the rat lung and aorta
in the delayed phase of endotoxic shock [9,11]. Nitrotyrosine
formation is often considered as a speci¢c ‘footprint’ of
ONOO3 [9,11,12], although recent studies suggest that tyro-
sine nitration may rather serve as an indicator of ‘reactive
nitrogen species’ [13,14]. However, these studies did not inves-
tigate the cellular sources of peroxynitrite. Since both poly-
morphonuclear and mononuclear leukocytes are capable of
producing high amounts of superoxide and NO in response
to LPS, we have investigated the time course of peroxynitrite
formation in human whole blood challenged with LPS. We
have utilized the oxidation of DHR 123 to rhodamine coupled
with the use of pharmacological inhibitors of NO synthase to
assess the intracellular formation and plasma accumulation of
biologically active peroxynitrite. This method has been em-
ployed for the measurement of peroxynitrite formation in vi-
tro [9,15]. Our results indicate that peroxynitrite-mediated
DHR 123 oxidation occurs in human granulocytes, monocytes
and lymphocytes in whole blood at early phases in response to
LPS, and these cells may contribute to the elevated plasma
levels of peroxynitrite during endotoxic shock.
2. Materials and methods
2.1. Materials
Bacterial lipopolysaccharide (E. coli, serotype O111:B4), aminogua-
nidine hemisulfate and NG-nitro-L-arginine methyl ester (L-NAME)
were purchased from Sigma Chemical Co. (St. Louis, MO, USA). NG-
nitro-D-arginine methyl ester (D-NAME) was obtained from Research
Biochemical International (Natick, MA, USA). DHR 123 and rhod-
amine were obtained from Molecular Probes (Eugene, OR, USA).
2.2. Whole blood incubation
Venous blood was collected into tubes containing heparin (25 U/ml)
from healthy volunteers (male and female, 21 to 52 years old) who
had not taken any drugs for at least 10 days before the experiments.
Informed consent was obtained from each volunteer, and the protocol
was approved by the Clinical Research Committee. White blood cell
counts were between 5500 and 9200 cells/Wl. Aliquots of whole blood
(1 ml) were placed on a rotator and challenged with LPS (1 Wg/ml) in
the presence or absence of L-NAME (10 mM), D-NAME (10 mM) or
aminoguanidine (10 mM) at 37‡C, 5% CO2 for the indicated time
periods. DHR 123 (20 WM) was added to the samples together with
LPS or 60 min before termination of the incubation period as indi-
cated.
2.3. Isolation and stimulation of lymphocytes
Mononuclear cells isolated from heparinized blood by centrifuga-
tion through Ficoll-Hypaque gradients (Pharmacia Diagnostics AB,
Uppsala, Sweden) were incubated on plastic culture dishes for 1 h at
37‡C in 5% CO2 in air. Non-adherent cells were then harvested and
resuspended in autologous plasma at 5U105 cells/ml. The resulting
cell preparation contained s 94% lymphocytes. Lymphocytes were
challenged with LPS (1 Wg/ml) for 4 h. DHR 123 (20 WM) was added
for the last 60 min of incubation.
2.4. Flow cytometry analysis
At the end of the incubation period, samples were prepared for £ow
cytometry analysis as described previously [16]. In brief, 100 Wl of
blood samples were mixed with 2 ml of a lysing medium (FACS
Lysing Solution, Becton-Dickinson) to lyse erythrocytes and ¢x leu-
kocytes, centrifuged and washed two times. Leukocytes were resus-
pended in PBS containing 0.5% formaldehyde. Single color £uores-
cence staining was analyzed by a cyto£uorometer (FACScan, Becton
Dickinson Immunocytometry Systems, Mountain View, CA, USA)
with Lysis II software. Data from 10 000 events per sample were
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acquired. Mean £uorescence intensity was determined after gating for
monocytes, lymphocytes and granulocytes by their forward and side
scatter characteristics. Background £uorescence was subtracted from
all samples. Leukocyte viability was assessed by using propidium
iodide (0.5 Wg/ml) as described previously [16].
2.5. Measurement of rhodamine accumulation in plasma
Plasma was harvested at the indicated times, and plasma rhodamine
level was measured with a spectro£uorometer (LS-5, Perkin-Elmer
Corporation, Norwalk, excitation 500 nm, emission 536 nm, slit
widths 3 nm). The amount of plasma rhodamine was quantitated by
using a rhodamine standard curve (0.8^400 nM) prepared in human
untreated plasma. Auto£uorescence and rhodamine concentrations
detected in autologous plasma incubated with DHR 123 for the
same time period have been subtracted from each sample.
2.6. Statistical analysis
Values are reported as mean þ S.E.M. of n observations. Statistical
analysis was performed by ANOVA using ranks (Kruskal-Wallis test)
followed by Dunn’s multiple contrast hypothesis test to evaluate dif-
ferences between various treatments. A P value s 0.05 was considered
signi¢cant for all tests.
3. Results
Addition of LPS to human whole blood caused, on average, a 2.4-fold increase in DHR 123 oxidation in granulocytes
within 30 min (Fig. 1, upper panel). The highest levels of
rhodamine were detected at 4 h following LPS challenge
(Fig. 1, upper panel), thereafter the amount of DHR 123
oxidized per 60 min decreased, but was still signi¢cantly high-
er than those detected at 1 h. The increases in DHR 123
oxidation at 30 and 60 min after addition of LPS were un-
a¡ected by L-NAME and aminoguanidine (Fig. 1, upper pan-
el). By contrast, the increased rhodamine £uorescence ob-
served after incubation of blood and LPS for longer periods
of time (4^24 h) were markedly, though never completely,
attenuated by inhibition of NO synthase with L-NAME or
aminoguanidine (Fig. 1, upper panel). For instance, L-NAME
and aminoguanidine reduced DHR 123 oxidation by 72 and
74%, respectively at 4 h following LPS. L-NAME and amino-
guanidine appeared to be equally potent inhibitors of DHR
123 oxidation at all time points studied. The D-enantiomer of
L-NAME, D-NAME had no signi¢cant e¡ect on LPS-in-
duced DHR 123 oxidation at any time points studied (data
not shown). Similar trends were observed in monocytes and
lymphocytes (Fig. 1, middle and lower panel). Rhodamine
£uorescence was similar in granulocytes and monocytes,
whereas it was one order of magnitude lower in lymphocytes
(Fig. 1, lower panel). As with granulocytes, both L-NAME
and aminoguanidine failed to prevent DHR 123 oxidation at
30 and 60 min after LPS, whereas both NO synthase inhib-
itors signi¢cantly attenuated DHR 123 oxidation at later
phases (Fig. 1, middle and lower panel). Viability of leuko-
cytes did not di¡er signi¢cantly in the absence or presence of
NO synthase inhibitors at any time point studied (data not
shown).
Increased rhodamine £uorescence was also observed in iso-
lated lymphocytes challenged with LPS for 4 h (relative £uo-
rescence intensity was 201 þ 25% of unstimulated cells, n = 5)
that was markedly attenuated by either aminoguanidine or L-
NAME (RFU: 114 þ 4% and 131 þ 8% of unstimulated cells,
respectively, n = 5, both P6 0.05).
The increases in intracellular DHR 123 oxidation were ac-
companied by a time-dependent accumulation of rhodamine
in the plasma (Fig. 2). A small, but statistically signi¢cant
increase in plasma rhodamine concentration was detected as
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Fig. 1. E¡ects of L-NAME and aminoguanidine (AG) on LPS-in-
duced dihydrorhodamine 123 (DHR 123) oxidation in human gran-
ulocytes (upper panel), monocytes (middle panel) and lymphocytes
(lower panel). Whole blood aliquots were left unstimulated (control)
or challenged with LPS (1 Wg/ml) in the absence or presence of ami-
noguanidine (AG, 10 mM) or L-NAME (10 mM). DHR 123 was
added during the last 60 min of incubation. Relative £uorescence in-
tensity (RFU) was determined by cyto£uorometry. Values are means
þ S.E.M. for four to ¢ve separate experiments. *P6 0.05 (compared
with control); SP6 0.05 (compared with LPS).
Fig. 2. Plasma levels of rhodamine after LPS. Aliquots of human
whole blood were left unstimulated (control) or challenged with
LPS (1 Wg/ml) in the absence and presence of aminoguanidine (AG,
10 mM) or L-NAME (10 mM) for the indicated time periods. DHR
123 (20 WM) was added to the samples together with LPS. Values
are means þ S.E.M. for four to ¢ve independent experiments.
*P6 0.05 (compared with control); SP6 0.05 (compared with
LPS).
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early as 1 h after addition of LPS (Fig. 2). This was not
inhibited by aminoguanidine or L-NAME. As with intracel-
lular DHR 123 oxidation, both aminoguanidine and L-
NAME markedly attenuated plasma rhodamine levels at 4,
8, 16 and 24 h incubation with LPS. No signi¢cant di¡erences
could be detected between the inhibitory e¡ects of the two NO
synthase inhibitors used (Fig. 2).
We have made an attempt to assess the amount of DHR
123 oxidized by leukocytes during 24 h incubation with LPS.
In these experiments, DHR 123 was added together with LPS.
Rhodamine £uorescence was on average 2.4-, 2.2- and 1.6-fold
higher in granulocytes, monocytes and lymphocytes in LPS-
stimulated blood than in unstimulated blood and was mark-
edly attenuated by aminoguanidine or L-NAME (Fig. 3).
4. Discussion
In this study, we have utilized the NO-dependent oxidation
of DHR 123 to rhodamine to assess intracellular formation of
peroxynitrite. This method is sensitive and speci¢c, because
while authentic peroxynitrite oxidizes DHR 123, neither NO
nor superoxide causes DHR 123 oxidation [15]. Therefore, it
is conceivable that DHR 123 oxidation that is blocked by NO
synthase inhibitors can be attributed to peroxynitrite forma-
tion. Rhodamine is retained intracellularly, since it is a selec-
tive vital stain for mitochondria in living cells [17].
Enhanced DHR 123 oxidation was detected in granulocytes
and monocytes as early as at 30 and 60 min after addition of
LPS to whole blood. However, this appears to be independent
of peroxynitrite formation, since inhibition of constitutive NO
synthesis with L-NAME failed to a¡ect DHR 123 oxidation.
Instead, the early DHR 123 oxidation could be attributed to
superoxide plus hydrogen peroxide, which in the presence of a
metal catalyst is known to oxidize DHR 123 to rhodamine
[18]. Previous studies have reported that NO donor com-
pounds inhibit peroxynitrite-mediated lipid peroxidation [19]
and endothelial dysfunction [20]. These ¢ndings coupled with
the observation of enhanced DHR 123 oxidation following
administration of L-NAME in normal, control rats [10,21]
raised the possibility of an NO-mediated inhibition of DHR
123 oxidation. Although both neutrophils and monocytes are
known to express constitutive NO synthase [22,23], the
amount of NO produced via this pathway might have been
insu⁄cient to inhibit e¡ectively DHR 123 oxidation in human
leukocytes. The lack of e¡ect of L-NAME on DHR 123 ox-
idation by leukocytes at 30 and 60 min post-LPS would lend
further support to the notion that peroxynitrite detected in the
rat plasma within 1 h of the onset of endotoxic shock is
formed by a reaction of superoxide (produced by activated
blood-borne and/or endothelial cells) with NO derived from
the constitutive, endothelial isoform of NO synthase [10]. L-
NAME inhibited endothelial NO production, leading to a
reduction of DHR 123 oxidation in the plasma of endotoxic
rats [10].
At later phases (4 to 24 h) of LPS stimulation, intracellular
DHR 123 oxidation can be prevented by either L-NAME,
which inhibits all forms of NO synthase, or aminoguanidine,
a selective inhibitor of inducible NO synthase [24,25], indicat-
ing formation of peroxynitrite in granulocytes, monocytes and
to a lesser extent in lymphocytes. While LPS-induced expres-
sion of inducible NO synthase in human neutrophil granulo-
cytes [22,23,26] and monocytes [22] has been described, little is
known about the expression of inducible NO synthase in lym-
phocytes. Interleukin-2-stimulated murine T lymphocytes [27]
and activated natural killer cells [28] were reported to synthe-
size NO, most likely via inducible NO synthase. LPS induced
increases in rhodamine £uorescence in isolated lymphocytes,
that can be prevented by either aminoguanidine or L-NAME,
indicating that DHR 123 oxidation detected in lymphocytes
can be attributed, at least in part, to peroxynitrite formation
by these cells. However, we cannot exclude the possibility that
DHR 123 oxidation was due to peroxynitrite that might have
di¡used into lymphocytes after its production by granulocytes
and monocytes. Indeed, a recent study suggests that peroxy-
nitrite could di¡use across the plasma membrane and will be
able to reach and di¡use into neighboring cells [29]. One
should consider the possibility that rhodamine might have
di¡used out of some cells and into others. However, addition
of rhodamine to unstimulated blood at concentrations (25
nM) similar to those detected in the plasma at 24 h post-
LPS, produced only slight increases in intracellular £uores-
cence, amounting to only 1^2% of the £uorescence detected
in leukocytes challenged with LPS. These observations
coupled with the fact that plasma rhodamine concentrations
in LPS-treated blood were three orders of magnitude lower
than those required for optimal staining of mitochondria (i.e.
20^30 WM) [17] suggest that increases in rhodamine £uores-
cence can be attributed to intracellular DHR 123 oxidation in
neutrophils, monocytes and lymphocytes. In addition to in-
hibition of inducible NO synthase, guanidines may also scav-
enge an intermediate derived from peroxynitrite [30].
Although this action of aminoguanidine might have contrib-
uted to prevention of DHR 123 oxidation, aminoguanidine
appears to be a rather weak peroxynitrite scavenger [30]. Con-
sistent with this observation, we could not detect signi¢cant
di¡erences between the inhibitory e¡ects of L-NAME and
aminoguanidine on LPS-induced DHR 123 oxidation. L-
NAME is unlikely to be a scavenger of peroxynitrite [31].
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Fig. 3. Intracellular oxidation of dihydrorhodamine 123 (DHR 123)
in human leukocytes challenged with LPS for 24 h. Human whole
blood aliquots were left unstimulated (control) or stimulated with
LPS (1 Wg/ml) in the absence or presence of aminoguanidine (AG,
10 mM) or L-NAME (10 mM). DHR 123 was added to the sam-
ples together with LPS. Relative rhodamine £uorescence intensity
(RFU) was determined by cyto£uorometry. Values are means
þ S.E.M. for ¢ve independent experiments. **P6 0.01 (compared
with control); SP6 0.05 (compared with LPS).
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Modest, though statistically signi¢cant increases in plasma
rhodamine concentration were detected as early as after 1 h
incubation with LPS. However, these were not due to peroxy-
nitrite production, because they cannot be prevented by the
NO synthase inhibitors. By contrast, at later phases of LPS
incubation, both L-NAME and aminoguanidine markedly at-
tenuated increases in plasma concentrations of rhodamine.
For instance, after 24 h incubation with LPS, about 66 to
86% of rhodamine accumulation in the plasma can be attrib-
uted to peroxynitrite formation. Recent results suggest that
peroxynitrite could react at a distance from its site of produc-
tion (i.e. 1^2 cell diameters) even in the presence of excess
target molecules [29]. Therefore, peroxynitrite could also oxi-
dize plasma DHR 123 following its release from leukocytes.
DHR 123 oxidation in the plasma has previously been used to
monitor peroxynitrite production in the rat [10]. However, it
is questionable whether rhodamine in plasma can be used as a
quantitative assay of peroxynitrite released from leukocytes,
because the plasma is a powerful peroxynitrite scavenger.
Based on rhodamine accumulation, the amount of peroxyni-
trite accumulated in the plasma during 24 h incubation with
LPS can be estimated as at least 60 to 80 nM, because oxi-
dation of each molecule of DHR 123 requires two molecules
of peroxynitrite [15]. The amounts of peroxynitrite produced
in whole blood might be even higher, for a signi¢cant portion
of peroxynitrite produced has been retained intracellularly, as
evidenced by the high rhodamine £uorescence detected in
granulocytes and monocytes at 24 h after LPS stimulation.
In conclusion, the present study demonstrates that human
leukocytes, in particular neutrophil granulocytes and mono-
cytes, can produce and release signi¢cant amounts of peroxy-
nitrite in response to LPS, thereby contributing to the in-
creased plasma levels of peroxynitrite in endotoxic shock.
Thus, it is plausible to assume that leukocyte-derived peroxy-
nitrite is one of the mediators of endothelial and vascular
dysfunction/damage.
Acknowledgements: This study was supported by a grant (MT-12573)
from the Medical Research Council of Canada.
References
[1] Beckman, J., Beckman, T., Chen, J., Marshall, P. and Freeman,
B. (1990) Proc. Natl. Acad. Sci. USA 87, 1620^1624.
[2] Beckman, S.J. and Crow, P.J. (1993) Biochem. Soc. Trans. 21,
330^334.
[3] Ischiropoulos, H., Zhu, L. and Beckman, J. (1992) Arch. Bio-
chem. Biophys. 298, 446^451.
[4] Kooy, N. and Royall, J. (1994) Arch. Biochem. Biophys. 310,
352^359.
[5] Haddad, I.Y., Pataki, G., Hu, P., Beckman, J.S. and Matalon, S.
(1994) J. Clin. Invest. 94, 2407^2413.
[6] Ma, T.T., Ischiropoulos, H. and Brass, C.A. (1995) Gastroenter-
ology 108, 463^469.
[7] Rachmilewitz, D., Stamler, J.S., Karmeli, F., Mullins, M.E., Sin-
gel, D.J., Loscalzo, J., Xavier, R.J. and Podolski, D.K. (1993)
Gastroenterology 105, 1681^1688.
[8] Kaur, H. and Halliwell, B. (1994) FEBS Lett. 350, 9^12.
[9] Wizemann, T.M., Gardner, C.R., Laskin, J.D., Quimones, S.,
Durham, S.K., Goller, N.L., Ohnishi, S.T. and Laskin, D.L.
(1994) J. Leukoc. Biol. 56, 759^768.
[10] SzaboŁ, C., Salzman, A.L. and Ischiropoulos, H. (1995) FEBS
Lett. 372, 229^232.
[11] SzaboŁ, C., Salzman, A.L. and Ischiropoulos, H. (1995) FEBS
Lett. 363, 235^238.
[12] Beckman, J.S. and Koppenol, W.H. (1996) Am. J. Physiol. 271,
C1424^C1437.
[13] Eiserich, J.P., Hristova, M., Cross, C.E., Jones, A.D., Freeman,
B.A., Halliwell, B. and van der Vliet, A. (1998) Nature 391, 393^
397.
[14] Halliwell, B. (1997) FEBS Lett. 411, 157^160.
[15] Kooy, W.N., Royall, A.J., Ischiropoulos, H. and Beckman, S.J.
(1994) Free Radic. Biol. Med. 16, 149^156.
[16] Filep, J.G., Delalandre, A., Payette, Y. and Foºldes-Filep, E.
(1997) Circulation 96, 295^301.
[17] Johnson, L.V., Walsh, M.J. and Chen, L.B. (1980) Proc. Natl.
Acad. Sci. USA 77, 990^994.
[18] Royall, J.A. and Ischiropoulos, H. (1993) Arch. Biochem. Bio-
phys. 302, 348^355.
[19] Rubbo, H., Radi, R., Trujillo, M., Telleri, R., Kalyanaraman, B.,
Barnes, S., Kirk, M. and Freeman, B.A. (1994) J. Biol. Chem.
269, 26066^26075.
[20] Villa, L.M., Salas, E., Darley-Usmar, M., Radomski, M.W. and
Moncada, S. (1994) Proc. Natl. Acad. Sci. USA 91, 12383^12387.
[21] Kurose, I., Wolf, R., Grisham, M., Aw, T., Specian, R. and
Granger, N. (1995) Circ. Res. 76, 30^39.
[22] Nathan, C. (1992) FASEB J. 6, 3051^3064.
[23] Carreras, M.C., Poderoso, J.J., Cadenas, E. and Boveris, A.
(1996) Methods Enzymol. 269, 65^75.
[24] Corbett, J.A., Tilton, R.G., Chang, K., Hasan, K.S., Ido, Y.,
Wang, J.L., Sweetland, M.A., Lancaster, J.R., Williamson, J.R.
and McDaniel, M.L. (1992) Diabetes 41, 552^556.
[25] Gri⁄ths, M.J.D., Messent, M., MacAllister, R.J. and Ewans,
T.W. (1993) Br. J. Pharmacol. 110, 963^968.
[26] Wheeler, M.A., Smith, S.D., Garcia-Cardena, G., Nathan, C.F.,
Weiss, R.M. and Sessa, W.C. (1997) J. Clin. Invest. 99, 110^116.
[27] Kirk, S.J., Regan, M.C. and Barbul, A. (1990) Biochem. Bio-
phys. Res. Commun. 173, 660^665.
[28] Filep, J.G., Baron, C., Lachance, S., Perreault, C. and Chan,
J.S.D. (1996) Blood 87, 5136^5143.
[29] Denicola, A., Souza, J.M. and Radi, R. (1998) Proc. Natl. Acad.
Sci. USA 95, 3566^3571.
[30] SzaboŁ, C., Ferrer-Sueta, G., Zingarelli, B., Southam, J.G., Salz-
man, L.A. and Radi, R. (1997) J. Biol. Chem. 272, 9030^9036.
[31] Rehman, A., Whiteman, M. and Halliwell, B. (1997) Br. J. Phar-
macol. 122, 1702^1706.
FEBS 20504 13-7-98
C. Gagnon et al./FEBS Letters 431 (1998) 107^110110
